Morepen Labs.

Who are the top shareholders of the Morepen Labs.?

The top shareholders of Morepen Labs include Pinfold Overseas Limited with 7.03%, Scope Credits And Financial Services Pvt. Ltd. at 2.84%, and individual investors collectively holding 48.76%. There are also 44 Foreign Institutional Investors with 1.94% and no pledged promoter holdings.

The top shareholders of Morepen Labs include a mix of individual and institutional investors. The largest public shareholder is Pinfold Overseas Limited, holding 7.03%. Among the promoters, Scope Credits And Financial Services Pvt. Ltd. has the highest stake at 2.84%. Additionally, individual investors collectively hold a significant portion of 48.76%. There are also 44 Foreign Institutional Investors (FIIs) with a combined holding of 1.94%, and two mutual fund schemes that hold 0.0%. Notably, there are no pledged promoter holdings.

What does Morepen Labs. do?

Morepen Laboratories Limited is an Indian pharmaceutical company specializing in the Pharmaceuticals & Biotechnology sector, with a market cap of Rs 3,517 Cr and reported net sales of 466 Cr and net profit of 20 Cr for March 2025. Key metrics include a P/E ratio of 30.00 and a return on equity of 10.21%.

Overview:<BR>Morepen Laboratories Limited is an India-based pharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap.<BR><BR>History:<BR>Morepen Laboratories was incorporated in the past, with the latest quarterly results reported for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 466 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 20 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap value: Rs 3,517 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.02<BR>- Return on Equity: 10.21%<BR>- Price to Book: 3.05<BR><BR>Contact Details:<BR>Address: Morepen Village, Nalagarh Road Near Baddi Solan Himachal Pradesh : 173205<BR>Tel: 91-01795-276201-03<BR>Email: investors@morepen.com<BR>Website: http://www.morepen.com

Has Morepen Labs. declared dividend?

No Dividend History Available

Who are the peers of the Morepen Labs.?

Peers of Morepen Labs include Guj. Themis Bio., Gufic BioScience, Orchid Pharma, Advanced Enzyme, Indoco Remedies, Senores Pharma, IOL Chemicals, Panacea Biotec, Novartis India, and Zota Health Care. Morepen Labs has average management risk and a 1-year return of 9.77%, which is higher than Orchid Pharma's -34.27% but lower than Panacea Biotec's 215.30%.

Peers: The peers of Morepen Labs. are Guj. Themis Bio., Gufic BioScience, Orchid Pharma, Advanced Enzyme, Indoco Remedies, Senores Pharma., IOL Chemicals, Panacea Biotec, Novartis India, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Guj. Themis Bio., Gufic BioScience, and Advanced Enzyme, while Average management risk is found at Morepen Labs., Indoco Remedies, IOL Chemicals, and Novartis India. Below Average management risk is present at Orchid Pharma, Senores Pharma., and Panacea Biotec. Growth is rated as Excellent for Senores Pharma., Good for Morepen Labs. and Novartis India, Average for Gufic BioScience, and Below Average for Guj. Themis Bio., Orchid Pharma, Advanced Enzyme, Indoco Remedies, IOL Chemicals, and Panacea Biotec. Capital Structure is Excellent for Guj. Themis Bio., Gufic BioScience, Advanced Enzyme, IOL Chemicals, and Novartis India, Average for Indoco Remedies, and Below Average for Orchid Pharma, Senores Pharma., and Panacea Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 215.30%, while the lowest is Orchid Pharma at -34.27%. Morepen Labs.'s 1-year return of 9.77% is significantly higher than that of Orchid Pharma but lower than that of Panacea Biotec. Additionally, Orchid Pharma and Panacea Biotec have negative six-month returns.

Who are in the management team of Morepen Labs.?

As of March 2023, the management team of Morepen Labs includes Sushil Suri (Chairman & Managing Director), Sanjay Suri (Whole-time Director), and several Non-Executive & Independent Directors: Manoj Joshi, Bhupender Raj Wadhwa, Sukhcharan Singh, Praveen Kumar Dutt, and Savita, along with Vipul Kumar Srivatava as Company Secretary & Compliance Officer.

As of March 2023, the management team of Morepen Labs includes the following individuals:<BR><BR>1. Sushil Suri - Chairman & Managing Director<BR>2. Manoj Joshi - Non-Executive & Independent Director<BR>3. Bhupender Raj Wadhwa - Non-Executive & Independent Director<BR>4. Sukhcharan Singh - Non-Executive & Independent Director<BR>5. Vipul Kumar Srivatava - Company Secretary & Compliance Officer<BR>6. Sanjay Suri - Whole-time Director<BR>7. Praveen Kumar Dutt - Non-Executive & Independent Director<BR>8. Savita - Non-Executive & Independent Director<BR><BR>Each member plays a distinct role in the governance and management of the company.

How big is Morepen Labs.?

As of 24th July, Morepen Laboratories Ltd has a market capitalization of 3,404.00 Cr, with net sales of 1,811.58 Cr and a net profit of 118.03 Cr reported in the latest four quarters. Shareholder's funds are 847.23 Cr, and total assets amount to 1,293.21 Cr as of March 2024.

As of 24th July, Morepen Laboratories Ltd has a market capitalization of 3,404.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Morepen Laboratories Ltd reported net sales of 1,811.58 Cr and a net profit of 118.03 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with shareholder's funds amounting to 847.23 Cr and total assets of 1,293.21 Cr.

Is Morepen Labs. overvalued or undervalued?

As of November 17, 2025, Morepen Labs is fairly valued with a PE ratio of 33.58, lower than Sun Pharma's 36.69 but higher than Cipla's 22.81, and has a low PEG ratio of 0.00, while underperforming the Sensex with a stock return of -38.87%.

As of 17 November 2025, Morepen Labs has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 33.58, an EV to EBITDA of 19.59, and a Price to Book Value of 2.12. <BR><BR>In comparison with its peers, Morepen Labs' PE ratio is lower than that of Sun Pharma, which stands at 36.69, but higher than Cipla's attractive valuation of 22.81. The PEG ratio for Morepen is notably low at 0.00, indicating potential growth concerns compared to peers like Divi's Lab, which has a PEG of 1.97. Additionally, Morepen Labs has underperformed the Sensex significantly over the past year, with a stock return of -38.87% compared to the Sensex's 9.50%.

Is Morepen Labs. technically bullish or bearish?

As of November 19, 2025, Morepen Labs is in a bearish trend with moderate strength, supported by bearish MACD and moving averages, while showing mixed signals from KST and underperforming against the Sensex.

As of 19 November 2025, the technical trend for Morepen Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is bearish, and the daily moving averages confirm this bearish outlook. Bollinger Bands are also indicating a bearish trend on both weekly and monthly time frames. The KST shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, indicating some mixed signals. Overall, the Dow Theory supports a mildly bearish view on both weekly and monthly time frames. The stock has underperformed significantly against the Sensex over various periods, further reinforcing the bearish sentiment.

How has been the historical performance of Morepen Labs.?

Morepen Labs has shown consistent growth in net sales and profitability, with net sales increasing from 768.54 crore in March 2019 to 1,811.58 crore in March 2025, and profit after tax rising from 28.84 crore to 118.02 crore in the same period. The company's total assets and liabilities also grew significantly, reflecting robust expansion.

Answer:<BR>The historical performance of Morepen Labs shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Morepen Labs has demonstrated significant growth in net sales, increasing from 768.54 crore in March 2019 to 1,811.58 crore in March 2025. The total operating income followed a similar trend, reaching 1,811.58 crore in March 2025, up from 853.07 crore in March 2020. The company's operating profit (PBDIT) also improved, rising to 192.43 crore in March 2025 from 71.19 crore in March 2019. Profit before tax increased to 155.11 crore in March 2025, compared to 29.18 crore in March 2019, while profit after tax reached 118.02 crore in March 2025, up from 28.84 crore in March 2019. The company's total assets grew significantly from 663.46 crore in March 2020 to 1,778.10 crore in March 2025, reflecting a robust expansion. Total liabilities also increased, from 663.46 crore in March 2020 to 1,778.10 crore in March 2025, indicating a rise in borrowings and other obligations. Cash flow from operating activities showed fluctuations, with a net cash inflow of 10 crore in March 2025, following a net outflow in the previous year. Overall, Morepen Labs has shown a strong upward trend in sales and profitability, alongside an increase in total assets and liabilities over the years.

When is the next results date for Morepen Laboratories Ltd?

The next results date for Morepen Laboratories Ltd is 10 February 2026.

The next results date for Morepen Laboratories Ltd is scheduled for 10 February 2026.

Are Morepen Laboratories Ltd latest results good or bad?

Morepen Laboratories Ltd's latest results show strong revenue growth with a record ₹484.16 crores for Q3 FY26, but a significant 32.69% decline in net profit raises concerns about profitability and investor confidence. Overall, the mixed signals suggest caution for potential investors.

Morepen Laboratories Ltd's latest results present a mixed picture. On one hand, the company achieved its highest-ever quarterly revenue of ₹484.16 crores for Q3 FY26, reflecting a strong sequential growth of 17.63% and a year-on-year increase of 6.93%. This indicates robust demand across its product portfolio, particularly in therapeutic categories such as antibiotics and respiratory products.<BR><BR>However, the profitability aspect raises concerns. The net profit for the quarter was ₹27.51 crores, which represents a significant decline of 32.69% compared to the previous quarter. This drop in profit is attributed to a higher effective tax rate and increased depreciation charges, leading to a PAT margin contraction to 5.68% from 9.97% in the prior quarter.<BR><BR>While the operating margin improved to 9.57%, the overall financial performance suggests challenges in translating revenue growth into sustainable profitability. Additionally, the stock has underperformed significantly over the past year, declining 31.65%, which reflects investor concerns about the company's growth trajectory and operational efficiency.<BR><BR>In summary, while Morepen Laboratories has demonstrated strong revenue growth, the substantial drop in net profit and ongoing concerns about capital efficiency and investor confidence indicate that the latest results are more negative than positive. Investors may want to approach the stock with caution given these mixed signals.

Should I buy, sell or hold Morepen Laboratories Ltd?

Why is Morepen Laboratories Ltd falling/rising?

As of 17-Mar, Morepen Laboratories Ltd's stock price is currently rising at 38.06, but it has a negative long-term performance with a year-to-date decline of 7.33% and a one-year drop of 11.07%. Despite a short-term increase, the overall outlook remains cautious due to declining sales, profit reductions, and low investor confidence.

As of 17-Mar, Morepen Laboratories Ltd's stock price is rising, currently at 38.06, with a change of 0.34 (0.9%) upward. This increase can be attributed to a trend reversal, as the stock has gained after two consecutive days of decline. Additionally, it has outperformed its sector by 0.62%. <BR><BR>However, despite this short-term rise, the stock has shown a negative performance over longer periods, with a year-to-date decline of 7.33% and a one-year drop of 11.07%. The stock is trading below its moving averages across various time frames, indicating a generally bearish trend. Furthermore, there has been a decrease in investor participation, with delivery volume falling by 10.6% compared to the five-day average, which may suggest waning interest among investors.<BR><BR>While the company maintains a low debt-to-equity ratio and is trading at a fair valuation relative to its peers, it has faced challenges such as a significant drop in profits by 39.5% over the past year and a low return on capital employed (ROCE) of 8.16%. The underperformance in the market, particularly against the BSE500, where the stock has generated negative returns while the market has seen positive returns, further complicates its outlook. <BR><BR>In summary, while the stock is experiencing a temporary rise, the broader context of declining sales, profit reductions, and low investor confidence suggests that the long-term outlook remains cautious.

Why is Morepen Laboratories Ltd falling/rising?

As of 18-Mar, Morepen Laboratories Ltd's stock price has risen to 38.65, reflecting a short-term gain despite a long-term negative return of -19.66% over the past year, indicating potential weakness and declining investor interest.

As of 18-Mar, Morepen Laboratories Ltd is experiencing a rise in its stock price, currently at 38.65, with a change of 0.59 (1.55%) upwards. This increase can be attributed to a few key factors. Firstly, the stock has outperformed its sector by 1.28% today and has shown a consecutive gain over the last two days, accumulating a total return of 2.47% during this period. <BR><BR>However, it is important to note that despite this recent uptick, the stock has been underperforming in the longer term. Over the past year, it has generated a negative return of -19.66%, significantly lagging behind the market, which has seen a return of 1.86%. Additionally, the stock is currently trading below its moving averages across various time frames, indicating a potential weakness in its price momentum.<BR><BR>Investor participation appears to be declining, as evidenced by a 37.87% drop in delivery volume compared to the five-day average. This suggests that while the stock is rising today, there may be underlying concerns regarding its long-term growth prospects, as reflected in its low debt-to-equity ratio and declining profits over the past year.<BR><BR>In summary, the recent rise in Morepen Laboratories Ltd's stock price is primarily driven by short-term performance, while longer-term indicators and investor sentiment suggest caution.

Why is Morepen Laboratories Ltd falling/rising?

As of 19-Mar, Morepen Laboratories Ltd's stock price is declining at Rs 37.06, down 4.11%, and has underperformed the sector. The stock is trading below all major moving averages, reflecting a bearish trend and significant negative returns over the past year.

As of 19-Mar, Morepen Laboratories Ltd's stock price is falling, currently at Rs 37.06, which reflects a decrease of Rs 1.59 or 4.11%. The stock has underperformed the sector by 1.96% today and has experienced a trend reversal after two consecutive days of gains. It reached an intraday low of Rs 36.92, marking a decline of 4.48%. <BR><BR>The stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, the broader Pharmaceuticals & Drugs sector has also seen a decline of 2.13%. Over the past year, Morepen Laboratories has generated a significant negative return of -25.09%, while its profits have decreased by 39.5%. This poor performance is compounded by low growth rates in net sales and operating profit over the last five years, which were 10.03% and 5.12%, respectively.<BR><BR>Investor sentiment appears to be cautious, as evidenced by the fact that domestic mutual funds hold 0% of the company, suggesting a lack of confidence in its current valuation or business prospects. Overall, the combination of declining stock performance, poor financial results, and negative market sentiment contributes to the falling stock price of Morepen Laboratories Ltd.

Why is Morepen Laboratories Ltd falling/rising?

As of 20-Mar, Morepen Laboratories Ltd's stock price is slightly up at 37.17, but it has declined 2.57% over the past week and 23.66% over the past year, indicating a long-term downward trend. Despite a recent uptick, the stock underperforms its sector and shows weak financial indicators, leading to a negative outlook.

As of 20-Mar, Morepen Laboratories Ltd's stock price is experiencing a slight rise, currently at 37.17, reflecting a change of 0.11 (0.3%) upward. However, this positive movement occurs against a backdrop of overall poor performance. Over the past week, the stock has declined by 2.57%, and it has seen a significant drop of 23.66% over the past year, indicating a long-term downward trend.<BR><BR>Despite the recent uptick in price, the stock is underperforming against its sector by 1.4% today and is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This suggests that the recent rise may not be indicative of a sustained recovery. Additionally, while there has been a rise in investor participation, with delivery volume increasing by 21.87% against the 5-day average, the overall sentiment remains cautious due to the company's financial performance. <BR><BR>The company has reported a decline in profits by 39.5% over the past year, and its return on equity (ROE) stands at a modest 6.3%. Furthermore, the stock has underperformed the broader market, with the BSE500 generating positive returns of 0.76% in the last year, contrasting sharply with Morepen's negative returns. <BR><BR>In summary, while there is a minor increase in the stock price today, the overall trend and financial indicators suggest that Morepen Laboratories Ltd is facing significant challenges, leading to a generally negative outlook.

Which are the latest news on Morepen Labs.?

Which are the latest news on Morepen Labs.?

Which are the latest news on Morepen Labs.?